Leuprorelina Gp-Pharm Depot Mensual (Leuprorelin Acetate)

Leuprorelin acetate binds to GnRH receptors in the pituitary gland, initially causing a brief rise in LH and FSH. Continued exposure desensitises the receptors, leading to a sustained drop in LH and FSH secretion, which in turn markedly reduces production of sex steroids like testosterone and estrogen.

The specific dose and dosing interval are determined by the prescribing clinician based on the indication, patient weight, and treatment goals. The product is supplied as a depot formulation for intramuscular injection, and the prescriber sets the exact regimen.

Leuprorelina Gp-Pharm Depot Mensual is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Leuprorelina Gp-Pharm Depot Mensual is a long‑acting depot formulation of leuprorelin acetate, offering sustained hormone suppression with monthly dosing. Compared with other GnRH agonists such as goserelin or triptorelin, it provides similar efficacy but may differ in dosing frequency, injection volume, and storage requirements, allowing clinicians to choose based on patient convenience and treatment protocol.

The depot injection should be stored at 2‑8 °C (refrigerated). Keep it in the original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, discard the product according to local regulations.

Leuprorelina Gp-Pharm Depot Mensual is administered by a healthcare professional as an intramuscular injection, typically into the gluteal muscle. The depot formulation releases the drug slowly over the dosing interval, providing continuous hormone suppression without the need for daily dosing.

Serious risks include significant bone‑density loss leading to osteoporosis, cardiovascular events such as myocardial infarction or stroke, severe allergic reactions (anaphylaxis), and acute adrenal insufficiency. Patients should be monitored regularly for these complications, especially if they have pre‑existing risk factors.

The product is contraindicated in pregnant women, individuals with known hypersensitivity to leuprorelin acetate or any excipients, and patients with severe uncontrolled cardiovascular disease. Caution is also advised for those with existing osteoporosis, liver impairment, or a history of severe allergic reactions.